Calyxt (CLXT) Misses Q4 EPS by 65c

Go back to Calyxt (CLXT) Misses Q4 EPS by 65c

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results

March 4, 2021 4:42 PM EST

Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual Meeting Partner Allogene Therapeutics presented initial results from Phase 1 ALPHA clinical study of licensed ALLO-501 in r/r NHL at 2020 ASCO Annual... More